Covid updates: Rajasthan, Gujarat, Bihar - the three big states - reported zero Covid deaths
India reported less than 20,000 Covid cases for the second day in a row. It reported 18,870 new cases, just marginally higher than yesterday's figures (18,795). The country also reported 378 deaths.
Here are the top 10 updates on coronavirus in India:
- The active cases comprise 0.84 per cent of the total infections, the lowest since March 2020, while the national COVID-19 recovery rate was recorded at 97.83 per cent, the highest since March 2020, the Union Heath Ministry said. A decrease of 9,686 cases has been recorded in the active COVID-19 caseload in a span of 24 hours.
- The daily positivity rate - number of positive cases identified per 100 - stands at 1.25 per cent less than 3 per cent for last 30 days.
- Out of 18,000-odd Covid cases, Kerala alone accounts for 11,196 of them. The state continues to report a high daily caseload, however the numbers have recently come down from the earlier 20,000 figure. The deaths in the state have jumped from 58 yesterday to 149 today.
- With 1,630 cases, Tamil Nadu is the second southern state after Kerala with a high daily Covid caseload. It also reported 19 Covid deaths.
- Maharashtra, the state with most number of Covid cases overall, reported 281 fresh cases over a 24-hour period. It also reported 60 deaths.
- Rajasthan, Gujarat, Bihar - the three big states - reported zero Covid deaths. Chhattisgarh, Uttarakhand also reported zero Covid deaths.
- Uttar Pradesh, the most populous state, reported 16 new cases and one Covid death. Neighbouring Delhi, the national capital, reported 34 cases and 2 Covid deaths.
- The coastal state of Goa, a big draw among tourists, reported 90 news cases and five Covid deaths.
- With 1,380 cases, Mizoram leads the northeastern states in most number of new Covid cases in a day. The state also reported four Covid deaths. It is followed by Assam, which reported 390 cases and 10 Covid deaths.
- The country's drug regulator has allowed vaccine maker Serum Institute to enrol kids aged 7-11 years for its trial of US drugmaker Novavax's COVID-19 vaccine. Serum Institute is already conducting a trial of its COVID-19 vaccine Covovax, a domestically produced version of Novavax's shot, in the 12-17 age group and has presented safety data for an initial 100 participants.The Novavax vaccine is yet to be granted approval by the health authorities.
Advertisement
Advertisement
Advertisement